; and (B) not less than 1 reviewer with commercialization expertise who is capable of assessing the likelihood of commercialization. ; (2) in subsection (o)— (A) in paragraph (4)(B)(i)— (i) by striking 1 year and inserting 180 days ; and (ii) by striking National Institutes of Health or the National Science Foundation and inserting Department of Health and Human Services, the National Science Foundation, or the Department of Agriculture ; (B) in paragraph (15), by striking and at the end; (C) in paragraph (16), by striking the period at the end and inserting ; and ; and (D) by adding at the end the following: (17) with respect to peer review carried out under the STTR program, to the extent practicable, include in the peer review— (A) the likelihood of commercialization in addition to scientific and technical merit and feasibility; and (B) not less than 1 reviewer with commercialization expertise who is capable of assessing the likelihood of commercialization. ; (3) in subsection (aa), by adding at the end the following: (6) Application of waiver The waiver authority under paragraph (4) shall not apply to Phase II awards that skip Phase I unless the additional funds are needed to respond to an urgent need in the United States, such as a pandemic. ; (4) in subsection (cc)— (A) by striking During fiscal years 2012 through 2022, the National Institutes of Health, the Department of Defense, and the Department of Education and inserting the following: (1) In general During fiscal years 2020 through 2025, each Federal agency with an SBIR or STTR program ; and (B) by adding at the end the following: (2) Limitation The total value of awards provided by a Federal agency under this subsection in a fiscal year shall be— (A) except as provided in subparagraph (B), not more than 10 percent of the total funds allocated to the SBIR and STTR programs of the Federal agency during that fiscal year